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Abstract: Recombinant human follicle stimulating hormone (rFSH) and luteinizing hormone 
(LH), also known as follitropin alpha and lutropin alpha, are manufactured by genetic engi-
neering techniques which ensure high quality and batch to batch consistency. Follitropin 
alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation 
induction for WHO group I and II anovulatory infertility and in men with hypogonadotrophic 
hypogonadism (HH) or idiopathic oligo-asthenospermia. Current evidence suggests superiority 
of urinary human menopausal gonadotropin (HMG) over follitropin alpha in controlled ovarian 
hyperstimulation for IVF in terms of live birth rate per couple. Addition of lutropin to follitropin 
alpha in an unselected IVF population does not appear to confer any benefit; however, it may 
have a role in ovulation induction in women with hypothalamic hypogonadism. Urinary HMG 
preparations (especially currently available highly purified preparations) are more cost effective 
than rFSH in terms of cost per ongoing pregnancy. However, women using rFSH injection pen 
devices have higher levels of satisfaction as compared to those using urinary HMG by means 
of conventional syringes.
Keywords: infertility, follicle stimulating hormone, luteinizing hormone, follitropin alpha, 
lutropin alpha, in-vitro fertilization, urinary gonadotrophins
Introduction
The pivotal role of the pituitary gland in reproductive function was established in 
the 20th century, when it became clear that it secreted two key hormones – follicle 
stimulating hormone (FSH) and luteinizing hormone (LH).1,2 This discovery allowed 
clinicians to treat infertile couples by means of pituitary extracts.2,3 Animal pituitary 
extracts of follicle stimulating hormone (FSH) were the first commercially available 
gonadotropins in the 1930s while the first use of cadaveric human gonadotropins 
for induction of ovulation was reported in 1958.4,5 Human pituitary gonadotropins 
(HPG) continued to be used in clinical practice for a number of decades before being 
withdrawn following reports of an association between its use and cases of Creutzfeld-
Jakob disease (CJD).5–7 Meanwhile, increasing demands for gonadotropins, which 
could not be met from cadaver specimens, led to the extraction and isolation of human 
menopausal gonadotropin (HMG) from urine in 1950.3 Human menopausal prepara-
tions contain both FSH and LH activity in a ratio of 1:1, though some of the LH activity 
was achieved by addition of human chorionic gonadotropin (HCG).8,9 Subsequently 
the development of advanced immunopurification and fractionation techniques using 
specific monoclonal antibodies led to the introduction of highly purified urinary 
preparations.3,5,10,11 More recently, use of genetic engineering technology led to the Biologics: Targets & Therapy 2010:4 
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development of the recombinant human gonadotropins 
preparations.12,13 Follitropin alpha was the world’s first 
recombinant human FSH preparation and lutropin alpha 
the first recombinant human luteinizing hormone (LH).14,15 
A mixture of follitropin alpha and lutropin alpha (follitropin 
alpha/lutropin alpha 150 IU/75 IU) has been recently com-
mercially available in a single product called PergoverisTM 
(Merck Serono).16 Biopatency studies have confirmed that the 
new drug is treated in the body similarly as if each product 
were administered separately.14,16 This combination could 
be of value for the stimulation of follicular development 
in infertile women with severe endogenous FSH and LH 
deficiency, using a single daily injection.17
Pharmacology
Structure
Follitropin alpha and lutropin alpha are glycoproteins which 
are structurally similar to endogenous FSH and LH. They 
possess similar alpha but different specific beta subunits.18,19 
The nomenclature “alpha” differentiates it from another 
recombinant human FSH product which was marketed later 
as follitropin beta.20
isoforms
Endogenous gonadotropins exist in a number of different 
isoforms which have similar amino acid sequences but differ 
in their terminal silaic acid content.21–24 Different isoforms 
can vary in their biophysical characters; but their clinical 
roles have yet to be determined.19,25,26 An isoform isolated 
at any particular time in the human body can be affected by 
gender, age, source of the sample, endocrine state and phase 
of menstrual cycle.27–29 Follitropin alpha is similar to the 
natural FSH isoform detected at mid cycle while Follitropin 
beta resembles that detected in the early follicular phase.30 
Recombinant FSH preparations differ from urinary HMG 
in their silaic acid content and have a shorter half life as 
they are more basic.9,31 Currently, lutropin alpha is the only 
commercially available recombinant LH preparation with a 
consistent isoform profile.32
Biological and specific activity
Biological activity of an agent is related to its effect on living 
tissue while specific activity represents its activity per unit 
mass. Follitropin alpha has a specific activity of 10,000 IU/mg 
which is similar to the urinary highly purified urofollitropin 
but is 100 times higher than that of other urinary derived 
FSH products.8,33 Follitropin alpha has been shown to induce 
follicular growth on its own without the addition of LH in 
most cases.34,35 However, the role of LH for optimal follicular 
development has been recently described – especially in 
profoundly LH deficient women with hypogonadotrophic 
hypogonadism.36,37 Although a minimum level of serum LH is 
required for optimum growth, excess LH can cause follicular 
growth arrest and prevent growing follicles from reaching 
the late antral stage.38,39 Follitropin alpha administration has 
been associated with a significant increase in serum levels 
of estradiol level, inhibin A and inhibin B.40,41 Significant 
increases in follicular levels of insulin and growth hormone 
have been detected in follitropin stimulated women.20
Pharmacokinetics
The pharmacokinetic properties of follitropin alpha and 
lutropin alpha are similar to those of urinary derived FSH 
and LH, respectively.20,42 Both are eliminated by means 
of the liver and kidney.42,43 Although subcutaneous (SC) 
administration is recommended, both products can also 
be administrated by the intramuscular route (IM).7,44 
Subcutaneous administration had been found to produce 
shorter absorption half life and time to maximum plasma 
concentration. Following a single subcutaneous 150 IU dose, 
follitropin alpha has a terminal half-life of about 37 hours, 
bioavailability of 74%, mean peak serum drug concentration 
(Cmax) 3 IU/L and the time to maximum plasma concentration 
(tmax) was 16 hours.45
Lutropin alpha has a one compartment first-order 
process.42 Following subcutaneous administration of 150 IU 
lutropin alpha, a mean Cmax of 1.1 IU/L is reached after 
6 hours (tmax).42 Lutropin alpha has a terminal half-life of 
about 18 hours and a bioavailability of 56% (following a 
single subcutaneous 10,000 IU dose).44
Manufacturing
Both follitropin alpha and lutropin alpha are manufactured 
by recombinant DNA technology.12,32 The gene encoded 
for the bio formation of each hormone is incorporated into 
a genetically engineered Chinese hamster cell line.20,46 The 
products of this cell line are then extracted and purified by 
means of a series of immunochromatograpic techniques.46,47 
which help to maintain quality assurance and batch to batch 
consistency.3,48,49 The current manufacturing process permits 
the follitropin alpha active ingredient to be quantified by 
its protein content (mass in µg); a technique called filled 
by mass (FbM) rather than the conventional method which 
relied on a product’s biological activity (bioassay).50,51 It 
has been suggested that the use of follitropin alpha filled by 
mass (FbM) may lead to more consistent ovarian stimulation, Biologics: Targets & Therapy 2010:4 
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less need to dose adjustment and fewer cycle cancellations.51,52 
The biological activity of lutropin alpha is determined by 
bioassay.53
Safety
General
Clinical trials have shown that follitropin alpha and lutropin 
alpha are very well-tolerated by patients. Ovarian hyper-
stimulation syndrome and multiple pregnancy are the most 
serious side-effects linked to gonadotropin use.54 Recombi-
nant FSH is not believed to increase the risk of miscarriage.55 
No fetal effects had been reported after accidental first 
trimester exposure to follitropin alpha.56 Headache, nausea, 
abdominal pain, breast pain, ovarian cyst formation are the 
most common side-effects of both follitropin alpha and 
lutropin alpha, while ovarian hyperstimulation is a serious, 
albeit rare side-effect.57
Side effects have been reported in 46.5% of patients who 
used follitropin alpha alone and 42.4% women receiving 
follitropin alpha/lutropin alpha. These include headache, 
nausea, mastalgia, fatigue, abdominal pain and development 
of functional ovarian cysts.6,20,33,53,57–59
A case report has described subclavian deep vein throm-
bosis and mild ovarian hyperstimulation associated with 
treatment with recombinant FSH.60 Bar et al have suggested 
diminished platelet aggregation in women using urinary 
FSH compared to rFSH.61 Local skin reaction including mild 
irritation, pain, erythema and pruritus has been reported in 
1.8% of a total of 1093 follitropin alpha injections.62 Subcu-
taneous injection of lutropin alpha was not associated with 
any adverse local skin reactions in almost 90% of the injected 
cases,36 only 3.4% women reported anything more than a 
mild skin reaction after SC injections with recombinant LH.37 
No antibodies to follitropin alpha have been discovered in 
women receiving any of these preparations.33,37,57 There were 
two case reports describing two separate IVF cycles where 
follitropin alpha was used successfully in inducing follicular 
growth in the absence of any allergic reactions in two women 
with severe allergic reactions to urinary FSH.63,64 Data from 
randomized trials and case series suggest that follitropin alpha 
is associated with better local tolerance and fewer injection 
site side effects than follitropin beta.65–67
OHSS
Severe ovarian hyperstimulation syndrome (OHSS) is a seri-
ous and a life-threatening complication with an incidence of 
about 0.5% to 2%.68,69 Polycystic ovarian syndrome (PCOS), 
previous episodes of OHSS and high doses of exogenous 
gonadotropins are known to increase the risk of developing 
OHSS.70–72 There is some evidence that individual sensitivity 
to FSH stimulation may be more important than the total 
amount of gonadotropins used.73 The incidence of OHSS in 
women in women using recombinant FSH in IVF treatment 
has been reported in two recent systematic reviews to range 
between 0% to 4.6% when rFSH was used for controlled 
ovarian hyperstimulation (COH) in IVF.74–76 The overall 
incidence was 2.6% after pooling results from 9 studies 
including a total of 1454 women in the rFSH group.68 There 
was no difference in the rate of OHSS between women on 
rFSH versus urinary FSH.77,78
After pooling results from 4 randomized trials including 
381 participants undergoing IVF in GnRH agonist down 
regulated cycles, the reported incidence of OHSS was 2.8% 
when lutropin alpha was co-administrated with rFSH.79 
Table 1 Classification of disorders of ovulation
Group Description Site of the lesion Hormone concentration
wHO
type i
Hypogonadotrophic
Hypo-estrogenic
Normoprolactinemic
Central Low FSH
Low estradiol
Normal prolactin
wHO
type ii
Hypogonadotrophic
Normo-estrogenic
Normoprolactinemic
Hypothalamic-pituitary
ovarian axis
Normal FSH
Normal estradiol
Normal prolactin
wHO
type iii
Hypergonadotrophic
Hypo-estrogenic
Normoprolactinemic
Ovarian failure High FSH
Low estradiol
Normal prolactin
Hyperprolactinemic Hyperprolactinemic Central Normal FSH
Normal estradiol
High prolactin
Adapted with permission from Shetty A. Disorders of ovulation. in: Templeton AA. ed. Management of Infertility for the MRCOG and Beyond. London: rCOG press; 2001.161 
Copyright © 2001 rCOG Press.
Abbreviation: FSH, follicle stimulating hormone.Biologics: Targets & Therapy 2010:4 
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There was no difference in the incidence of OHSS between 
women who received rLH plus rFSH and those who received 
rFSH alone.79
Multiple pregnancy
Gonadotropin stimulation of the ovaries in assisted reproduc-
tion leads to multifollicular growth.80,81 Unlike IVF, where 
the number of embryos replaced determines the incidence of 
multiple gestations,81 the release of more than one oocyte in 
ovulation induction or superovulation with IUI could poten-
tially increase chances of multiple pregnancy.82 Phase III 
trials of follitropin alpha show a multiple birth rate of 20% 
when the drug is used for ovulation induction and 35% when 
it is used in IVF.53
A number of different strategies have been proposed to 
decrease the chance of multiple births after ovulation induc-
tion but their impact has been limited.54 The two systematic 
reviews of trials comparing rFSH to urinary HMG in IVF 
showed no difference in multiple pregnancy rates between 
the two treatment groups.77,78
Clinical efficacy
FSH and LH have significant roles in ovarian follicle 
differentiation, selection and survival.83 Exogenous gonado-
tropin administration has been suggested as an effective 
means of treatment in WHO group I and II anovulation, 
and in males with hypogonadotrophic hypogonadism.59,84,85 
In normogonadotropic women, COH is an essential prereq-
uisite for successful in vitro fertilization (IVF) treatment.86 
The aim in IVF is to stimulate multiple follicular growth 
in order to enhance the increase the yield of oocytes.87 
Superovulation is also used in conjunction with intrauterine 
insemination even in absence of evidence of anovulation, 
though the rationale for this intervention has been challenged 
recently.88,89
Different protocols for COH had been described. In IVF, 
these protocols usually involve pituitary suppression by 
GnRH agonists or antagonists.90–92 Variable long, short 
or ultrashort protocols for GnRH agonists have been sug-
gested.90,93 The commonest is the long luteal phase protocol 
where GnRH agonists are started in the luteal phase of the 
cycle preceding the IVF cycle.94,95
Efficacy in IVF/ICSI
Follitropin alpha
Recently, two systematic reviews of randomized trials 
comparing recombinant FSH (rFSH) and urinary HMG 
(uHMG) in unselected subfertile women undergoing 
IVF/ICSI (intracytoplasmic sperm injection of eggs), have 
been published.77,78
In the first, results from a meta-analysis of 12 randomized 
controlled trials (RCTs), with a total of 2937 participants 
have shown an overall live birth rate of 21.8% in the rFSH 
group compared to 24.9% in the uHMG group.77 The second 
systematic review included only 7 RCTs which compared 
rFSH and HMG in IVF cycles where a long pituitary down-
regulation protocol was used.78 The pooled results based on 
a total of 1259 women showed that the live birth rate per 
woman treated with rFSH was 21.6% compared to 25.4% 
in the HMG group (Figure 1).78
Al-Inany et al77 found live birth rate per woman in the 
HMG group to be significantly higher than in the rFSH 
group (odds ratio [OR] 1.20, 95% confidence interval [CI] 
1.01 to 1.42).77 Coomarasamy et al78 showed live birth rate 
per woman in the uHMG group to be significantly higher 
than the rFSH group (OR 1.18, 95% CI 1.02 to 1.38).78 
These results are based on a general population of women 
undergoing IVF. It has been suggested that specific groups 
of patients such as older women or poor responders might 
benefit from rFSH.96,97 However, there is a need for relevant 
evaluative studies in order to elucidate the role of rFSH in 
those women. Neither systematic review has shown any dif-
ferences in rates of multiple pregnancy rates, ovarian hyper-
stimulation or miscarriage.77,78 Unlike Coomarasamy and his 
colleagues, Al-Inany et al reported a significant reduction in 
dose and duration of stimulation and available embryos in 
the rFSH group.77
Traditional uHMG preparations contained FSH and LH 
in a ratio of 1:1, while more recent highly purified FSH 
(HP FSH) products using monoclonal antibody techniques 
for extraction and purification of FSH contain negligible 
amounts of LH (P  0.001%).8 In their systematic review,77 
Al-Inany et al examined the effect of the type of HMG 
(purified versus conventional) compared with rFSH on IVF 
outcome. They performed a subgroup analysis to compare 
HP HMG with rFSH and showed a similar outcomes in 
the HP-HMG group in terms of live birth rate (OR 1.21, 
95% CI 1.02 to 1.44) and clinical pregnancy rate (OR 1.26, 
95% CI 1.04 to 1.53).77 Two recent RCTs, one using a long 
downregulation protocol along with a GnRH agonist and 
the other a GnRH antagonist, failed to demonstrate any 
significant difference in pregnancy rates between HPFSH 
and rFSH.98,99
Follitropin alpha and follitropin beta represent two iso-
forms of the same molecule.20 Although some authors have 
suggested a difference in clinical efficacy between the two Biologics: Targets & Therapy 2010:4 
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molecules,13,100 live birth rates and clinical pregnancy rates 
have been shown to be comparable in four randomized con-
trolled trials.65,101–103
Lutropin alpha in ivF
It has been reported that high LH levels in the follicular phase 
of the IVF cycle could have a detrimental effect on the outcome 
of IVF104,105 but a minimum threshold serum concentration of 
LH is required for optimum folliculogenesis.38 According to 
Loumaye and colleagues, the effect of LH on the growing 
cohort of follicles demonstrates a ceiling effect and exceeding a 
certain threshold can compromise follicular development.38
Results of a recent Cochrane review do not confirm an 
increase in live birth rates associated with the addition of 
rLH to rFSH in GnRH agonist downregulated IVF cycles 
compared to rFSH only stimulated cycles (two trials: OR 
1.51, 95% CI 0.79 to 2.87).79
Meta-analyses of RCTs where GnRH antagonists (rather 
than GnRH agonist) were used for pituitary suppression also 
failed to find any significant differences in terms of clinical 
pregnancy rates, as none of the studies included reported 
live birth.79
There was no difference in the risk of early miscarriage 
between women on rFSH who were co-treated with rLH 
(eight trials: OR 0.59, 95% CI 0.35 to 1.02) compared to 
women who were treated with rFSH alone.79 However, after 
exclusion of a single trial that used a flare up GnRH protocol, 
a trend towards reduced miscarriage rates (of borderline sig-
nificance) was found in women co-treated rLH (seven trials: 
OR 0.57, 95% CI 0.33 to 1.00). There was a significant dif-
ference in live birth rate in favor of rLH supplementation in 
poor responders (three trials: OR 1.85, 95% CI 1.10 to 3.11). 
There were no differences in other IVF outcomes such as 
OHSS, number of oocytes retrieved, amount of rFSH used, 
serum estradiol level on the day of HCG administration and 
miscarriage rate.79
These findings are in accordance with results from a 
previous meta-analysis of results from 4 RCTs examining 
the effect of adding rLH to rFSH in GnRH agonist down-
regulated IVF cycles.106
An RCT which included 84 participants found no signifi-
cant difference in pregnancy rate between poor responders 
treated with either rFSH alone or rLH and FSH in an GnRH 
agonist flare up protocol.107
In a systematic review where trials using GnRH agonists 
and antagonist cycles were pooled, live birth rates and clinical 
pregnancy rates were similar regardless of whetherrLH was 
co-administrated with rFSH or not.108
Although some clinicians have reported that rLH 
administration prior to rFSH in IVF cycles increased the 
number of antral follicles, this did not translate into improved 
rates of live birth pregnancy.109 Thus, there is no evidence 
at the present time that co-administration of rLH to rFSH, 
in controlled ovarian hyperstimulation for IVF, has a 
beneficial effect in IVF.
In the European Union, a combination of follitropin alpha 
and lutropin alpha (Pergoveris™) is currently available for 
single subcutaneous injection.17 The ratio of follitropin alpha 
to lutropin alpha in that preparation is 2:1, respectively. 
A randomized crossover trial had demonstrated bioequiva-
lence between follitropin alpha and lutropin alpha adminis-
tered alone or in this fixed 2:1 combination.110
Use of follitropin alpha in ovulation 
induction
Hypogonadotrophic hypogonadism
WHO group I anovulation is a rare condition that can be 
caused by a hypothalamic or pituitary defect due to congenital 
or acquired causes (Table 1).111 Management options include 
exogenous replacement of gonadotropins and pulsatile GnRH 
agonist administration.112 In women with intact pituitary 
function, pulsatile gonadotropin releasing hormone (GnRH) 
therapy can be used.113 The advantages of pulsatile GnRH 
compared with gonadotropins are that there is a lower risk of 
hyperstimulation and multiple pregnancies and the need for 
monitoring is minimal.36 Exogenous gonadotropins adminis-
tration is the alternative therapeutic option in hypothalamic 
dysfunction and the first line treatment if the defect is primary 
pituitary failure.113,114
Currently available evidence indicates that rFSH 
alone may not be sufficient to promote optimum follicu-
lar growth in severely gonadotropin deficient women.37 
It has been suggested that a minimum threshold of serum 
LH is required to re-establish meiosis and final stages of 
growth of antral follicles. Meanwhile, follicular growth 
arrest might occur, should LH exceed that threshold, in 
what is called an LH ceiling. Antral follicle growth arrest 
(at 10 mm diameter) has been observed in LH deficient 
cycles.38
A dose finding trial included 38 WHO type I anovulatory 
patients, who were randomly assigned to receive either 0, 
25, 75, or 225 IU rLH once daily in addition to 150 IU 
follitropin alpha once daily for up to 20 days. None of the 
8 patients who received follitropin alpha alone ovulated in the 
absence of rLH. Fourteen percent of patients who received 
follitropin alpha and 25 IU/L rLH ovulated compared to Biologics: Targets & Therapy 2010:4 10
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66% and 80% of those who received 75 IU/L and 225%, 
respectively.37 Significant dose dependent increases in 
the rate of optimal follicular growth were observed in 
women receiving follitropin alpha with different doses of 
rLH varying from 0 to 225 IU/day.37,84 Another random-
ized trial has shown significantly higher rates of optimum 
follicular growth in severely deficient LH women taking 
follitropin alpha plus lutropin alpha than those who were 
taking follitropin alpha with placebo.115 A case series from 
Spain included 38 hypogonadotrophic anovulatory (WHO 
group I) women undergoing 84 ovulation induction cycles 
where patients received 150 IU/day rFSH and 75 IU/day rLH. 
Sufficient follicular growth was observed in 79 (94%) out 
of 84 initiated cycles. The 75 IU rLH dose was found to be 
effective in 94% of the treatment cycles.36 The cumulative 
pregnancy rate following three cycles of stimulation with 
follitropin alpha and lutropin alpha was 39.5%.36 Clinical 
pregnancy occurred in 16 out of the 31 women received 
lutropin alpha with follitropin alpha in an extension phase 
of the randomized trial published by O’Dea et al in 2000 
on severely hypogonadotrophic women.116 Two case reports 
documented pregnancies in 2 women with Kallman syn-
drome (amenorrhea, anosmia and hypogonadotrophic 
hypogonadism) and empty sella syndrome who received 
follitropin alpha and rLH.117,118
wHO group ii anovulation
It had been estimated that 90% of women in women in 
WHO type II anovulation would be expected to have 
polycystic ovarian syndrome (PCOS).119 According to the 
Rotterdam consensus criteria, PCOS should be considered 
when two of three features are diagnosed; ovarian 
dysfunction, features of hyperandrogenism (clinical or 
biochemical) and PCO morphology.120 Although serum LH 
is not included as a diagnostic feature, the large majority 
of women with PCOS would have excess elevated LH 
concentrations when measured at the appropriate time.121 
This may justify the potential advantages in preparations 
devoid of LH activity as follitropin alpha. Currently, there 
is no role of lutropin alpha in the management of women 
with PCOS.
The first baby born after ovulation induction by 
follitropin in a clomiphene resistant PCOS patient 
was reported in 1992.122 Randomized trials comparing 
follitropin alpha to other gonadotropins preparation or 
other ovulatory medications, in infertile women with 
WHO type II anovulation, have reported a live birth rate of 
17% to 20%.59,123,124 The rate of successful ovulation has been 
reported to be between 57% and 85%.33,125–127 The pooled 
ovulation rate per cycle after rFSH in clomiphene citrate 
resistant PCOS women has been calculated to be 71% in 
a Cochrane review (Figure 2).128 Recent randomized trials 
have reported higher ovulation rates from 85% and up to 
97% in this group of women.59,103,127 with comparable clinical 
pregnancy rates per woman ranging from 17% to 20% after 
one cycle,59,103,126 and a cumulative clinical pregnancy rate 
per woman of 42%.128 A similar cumulative live birth rate of 
43% was reported by a subsequent RCT.129
There were no significant differences in ovulation rates, 
pregnancy rates or live birth rates between follitropin alpha 
and highly purified FSH59,103,125 However, a small RCT 
showed more favorable pregnancy rates with rFSH com-
pared to urinary FSH.130 Two protocols have been suggested 
for ovulation induction with gonadotropins in this group of 
patients.131 In the step-up protocol the FSH dose is increased 
by 75 IU every 5 to 7 days, while in the low-dose regimen, 
it is administrated at a low dose for 14 days followed 
by small incremental dose increases (when necessary), 
at intervals not shorter than 7 days, until follicular develop-
ment is initiated.66,112,132 The type of the protocol, has not 
been shown to affect ovulation or pregnancy rates in studies 
using follitropin alpha.59,62 However, the low dose protocol 
significantly reduces the incidence of OHSS and multiple 
pregnancy.69,132
Male subfertility
FSH and LH are gonadotropins and have an important 
role in the process of spermatogenesis, though the actual 
mechanism of action is poorly understood.133 LH may 
stimulate testosterone secretion from the Leydig cells of 
the testicle, while FSH stimulates Sertoli cells to facilitate 
germ cell differentiation.134 Follitropin alpha alone or with 
human chorionic gonadotropin (HCG) had been used to 
improve sperm parameters in male factor infertility.135 
A Cochrane review included RCTs that compared pregnancy 
rates (spontaneous and after ART) following treatment of 
couples with idiopathic male factor infertility with urinary 
or recombinant gonadotropins (compared to placebo or 
no treatment), showed a significantly higher spontaneous 
pregnancy rate per couple randomized within three months 
of completing gonadotropin therapy (OR 4.17, 95% CI 
1.30 to 7.09). However, there were only three trials with 
a total of 234 participants and the authors concluded that 
more studies were needed to confirm this finding.133 The 
two RCTs included in this meta-analysis, where follitropin 
alpha was administered, showed no significant difference Biologics: Targets & Therapy 2010:4 11
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in pregnancy rates between groups which received rFSH 
injections compared to those which received placebo or no 
treatment.136,137 Treatment of azospermic men with rFSH for 
10 months prior to ICSI may lead to detection of sperms in 
the ejaculate and spare these men surgical sperm retrieval 
procedures.138 As age of the female partner is considered the 
single most important factor in predicting success of other 
interventions such as ICSI, the benefit of this relatively long 
period of treatment may need to be weighed up against the 
expected advancement in maternal age, especially in women 
above 35.
There are few data on the use of lutropin alpha in male 
factor infertility. Due to its structural similarity, purified 
HCG may be an effective substitute for LH as the two 
hormones act through the same Leydig cell receptor.139 
In normal men, a single IV injection of 150 IU lutropin 
induces a 25% rise in plasma testosterone levels by com-
parison with placebo.140 We are not aware of any published 
randomized trials investigating the effect of lutropin alpha 
for male factor infertility.
In males with hypogonadotrophic hypogonadism pre-
sented by azospermia or sever oligoasthenoteratospermia, 
rFSH may be effective in achieving spermatogenesis when 
combined with HCG.141–144 Combined analysis of data from 
four clinical trials shows that HCG and rFSH induced 
spermatogenesis in 84% of men with hypogonadotrophic 
hypogonadism.145 A number of baseline factors, including 
mean testicular volume, body mass index, age of disease 
onset and response to previous therapy, has been shown to 
influence the response.145,146
Patient satisfaction
Recombinant FSH can be used either as subcutaneous or 
intramuscular injection. Both follitropin alpha and beta 
are currently available in prefilled pen like devices for self 
injection. This delivery system has been shown to improve 
patient compliance and satisfaction.82,147,148 A randomized 
trial comparing follitropin alpha in a pen device to the 
conventional syringe has shown that the former is associ-
ated with significantly higher rates of self-administration 
and satisfaction, with significantly less pain and local reac-
tions at the injection site.149 A questionnaire based study on 
ease-of-use, safety and efficacy of two follitropin injection 
pens found the follitropin alpha pen to be effective, well 
tolerated with higher patient and nurse acceptance than the 
follitropin beta pen.150
Economic evaluation
A number of economic analyses comparing rFSH versus 
uHMG have been published.151–154 Two studies compared 
hMG   rFSH RR (fixed)
95% Cl n/N n/N (%) 95% Cl
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Figure 1 Meta-analysis of randomized trials of hMG versus rFSH following a long down-regulation protocol for the outcome of live births. Adapted with permission from 
Coomarasamy A,   Afnan M, Cheema D, van der  veen F, Bossuyt PM, van wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist 
long down-regulation protocol in ivF or iCSi treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23(2):310–315.78 Copyright © 2008 Oxford University Press.
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highly purified FSH with rFSH.155,156 Results from these 
studies, which were supported directly or indirectly by 
pharmaceutical companies, were conflicting. One of these 
analyses156 was based on data from a large randomized trial 
comparing the use of HP HMG to rFSH in IVF treatment.73 
The results have shown urine-derived highly purified HMG 
to be a cost-effective alternative to follitropin alpha. The 
median cost per live birth was significantly lower in the HP 
HMG group than in the rFSH group (£8893 and £11741, 
respectively, P  0.001).156
An economic analysis based on data from a meta-analy-
sis of 8 RCTs, comparing rFSH to uHMG, has estimated an 
average cost of an ongoing pregnancy at 13,946 Egyptian 
pounds (EGP) for a HMG cycle versus 18,721 (EGP) for 
a rFSH cycle.157,158 This economic analysis was based on 
the prices of rFSH and uHMG in the Egyptian market 
(150 Egyptian pounds for 75 IU rFSH, and 50 Egyptian 
pounds for 75 IU uHMG). The cost was calculated on 
the base of the fees charged by the authors’ IVF center. 
Al-Inany et al showed that a 60% reduction in the cost 
of rFSH would be needed in order to provide a cost per 
ongoing IVF pregnancy similar to that achieved with 
uHMG.158 HMG use would result in 4565 more pregnan-
cies in a hypothetical model based on 100,000 IVF cycles. 
Wechowski et al156 estimated that the savings associated with 
HP-HMG (as opposed to rFSH) would fund one additional 
IVF cycle in every 10 cycles while Lloyd et al155 projected 
a 13% increase in the number of cycles possible with the 
same budget.155,156
The use of uHMG for ovulation induction in anovulatory 
women can lead to 9.4% reduction in the cost per live birth.124 
Two separate economic analyses have demonstrated that 
uHMG is more cost-effective than rFSH in superovulation 
with IUI.159,160
Conclusion
Follitropin alpha and lutropin alpha are human rFSH and 
rLH, respectively. They are manufactured by genetic engi-
neering techniques which ensure high quality and batch to 
batch consistency. Current evidence suggested superiority 
of uHMG over follitropin alpha in controlled ovarian hyper-
stimulation for IVF in terms of live birth rate per couple. 
Currently, there is no evidence to recommend the routine 
use of lutropin to follitropin alpha in an unselected IVF 
population. The use of follitropin alpha is comparable to HP 
FSH for ovulation induction in WHO group II anovulation. 
There is evidence that uHMG preparations (especially cur-
rently available highly purified preparations) are more cost 
effective than rFSH in terms of cost per ongoing pregnancy. 
However, patient satisfaction and quality of life in women 
using rFSH injection pen devices are higher than those using 
the conventional syringes for uHMG.
Disclosures
The authors declare no conflicts of interest.
References
  1.  Smith MG. On the interruption of pregnancy in the rat by the injection of 
ovarian follicular extract. Bull Johns Hopkins Hosp. 1926;39(4):203–214.
  2.  Fevold SL, Hisaw FL, Leonard SL. The gonad-stimulating and the 
luteinizing hormones of the anterior lobe of the hypophysis. Am J 
Physiol. 1931;97:291–301.
  3.  Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum 
Reprod Update. 2004;10(6):453–467.
Review: Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome
Comparison: 1 Rec-FSH versus urinary FSH
Outcome: 2 Pregnancy rate (per patient)
Study or subgroup Treatment
n/N
Control
n/N
Peto Odds Ratio
Peto, Fixed, 95% Cl
Coelingh Bennink167
Loumaye168
Yarali125
32/105
8/16
46/110
19/67
13/35
54/112
34.2%
10.8%
55.0%
1.68 [0.51, 5.53]
0.77 [0.46, 1.31]
1.11 [0.57, 2.16]
100.0% 0.95 [0.64, 1.41] 214 231 Total (95% CI)
Total events: 86 (Treatment), 86 (Control)
Heterogeneity: Chi2 = 1.67, df = 2 (P = 0.43: I2 = 0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Favours Treatment Favours Control
10.0 5.0 2.0 1.0 0.5 0.2 0.1
Weight Peto Odds Ratio
Peto, Fixed, 95% CI
Figure 2 Meta-analysis of randomized trials of hMG versus rFSH for the outcome of pregnancy rate per patient in women undergoing ovulation induction for subfertility associated 
with polycystic ovarian syndrome. Bayram N, van wely M, van Der veen F. recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in sub-
fertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2001;2(2):CD002121.128 Copyright © Cochrane Collaboration, reproduced with permission.
Abbreviations: HMG, human menopausal gonadotropin; rFSH, recombinant follicle stimulating hormone.Biologics: Targets & Therapy 2010:4 13
recombinant follitropin alfa/lutropin alfa in fertility treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  4.  Gemzell CA, Diczfalusy E, Tillinger G. Clinical effect of human 
pituitary follicle-stimulating hormone (FSH). J Clin Endocrinol Metab. 
1958;18(12):1333–1348.
  5.  Lunenfeld B. Development of gonadotrophins for clinical use. Reprod 
Biomed Online. 2002;4 Suppl:111–117.
  6.  Dumble LJ, Klein RD. Creutzfeldt-Jakob legacy for Australian 
women treated with human pituitary gonadotropins. Lancet. 
1992;340(8823):847–848.
  7.  Cochius JI, Burns RJ, Blumbergs PC, Mack K, Alderman CP. 
Creutzfeldt-Jakob disease in a recipient of human pituitary-derived 
gonadotrophin. Aust NZ J Med. 1990;20(4):592–593.
  8.  Strowitzki T. Biotechnological drugs for reproductive disorders: a review 
of developments. BioDrugs. 1997;8(5):360–370.
  9.  Gordon K. New developments in gonadotrophin pharmacology. Reprod 
Biomed Online. 2002;5(3):259–264.
10.  Giudice LC. Insulin-like growth factor family in Graafian follicle 
development and function. J Soc Gynecol Investig. 2001;8(1 Suppl 
Proceedings):S26–S29.
11.  Wolfenson C, Groisman J, Couto AS, et al. Batch-to-batch consistency 
of human-derived gonadotrophin preparations compared with recom-
binant preparations. Reprod Biomed Online. 2005;10(4):442–454.
12.  Howles CM. Genetic engineering of human FSH (Gonal-F). Hum 
Reprod Update. 1996;2(2):172–191.
13.  Olijve W, de Boer W, Mulders JW, van Wezenbeek PM. Molecular 
biology and biochemistry of human recombinant follicle stimulating 
hormone (Puregon). Mol Hum Reprod. 1996;2(5):371–382.
14.  Alper M, Meyer R, Dekkers C, Ezcurra D, Schertz J, Kelly E. Assess-
ment of the biopotency of follitropin alfa and lutropin alfa combined 
in one injection: a comparative trial in Sprague-Dawley rats. Reprod 
Biol Endocrinol. 2008;6:31–36.
15.  Saz-Parkinson Z, López-Cuadrado T, Bouza C, Amate JM. Outcomes 
of new quality standards of follitropin alfa on ovarian stimulation: 
meta-analysis of previous studies. BioDrugs. 2009;23(1):37–42.
16.  Agostinetto R. Administration of follitropin alfa and lutropin alfa 
combined in a single injection: a feasibility assessment. Reprod Biol 
Endocrinol. 2009;7:48–52.
17.  http://www.emea.europa.eu/humandocs/PDFs/EPAR/pergoveris/ 
H-714-en1.pdf
18.  Pierce JG, Faith MR, Giudice LC, Reeve JR. Structure and structure-
function relationships in glycoprotein hormones. Ciba Found Symp. 
1976;41:225–250.
19.  Gordon K, Prins M, Schuller K, Lewin J. One million and counting. 
Reprod Biomed Online. 2006;13(3):313–314.
20.  Goa KL, Wagstaff AJ. Follitropin alpha in infertility: a review. BioDrugs.   
1998;9(3):235–260.
21.  Wide L, Bakos O. More basic forms of both human follicle-stimulating 
hormone and luteinizing hormone in serum at midcycle compared with 
the follicular or luteal phase. J Clin Endocrinol Metab. 1993;76(4): 
885–889.
22.  Papandreou MJ, Asteria C, Pettersson K, Ronin C, Beck-Peccoz P. Con-
canavalin A affinity chromatography of human serum gonadotropins: 
evidence for changes of carbohydrate structure in different clinical 
conditions. J Clin Endocrinol Metab. 1993;76(4):1008–1013.
23.  Green ED, Baenziger JU. Asparagine-linked oligosaccharides on 
lutropin, follitropin, and thyrotropin. II. Distributions of sulfated and 
sialylated oligosaccharides on bovine, ovine, and human pituitary 
glycoprotein hormones. J Biol Chem. 1988;263(1):36–44.
24.  Dahl KD, Stone MP. FSH isoforms, radioimmunoassays, bioassays, and 
their significance. J Androl. 1992;13(1):11–22.
25.  Andersen AN, Devroey P, Arce JC. Clinical outcome following stimula-
tion with highly purified hMG or recombinant FSH in patients under-
going IVF: a randomized assessor-blind controlled trial. Hum Reprod. 
2006;21(12):3217–3227.
26.  Lambert A, Rodgers M, Mitchell R, et al. In-vitro biopotency and 
glycoform distribution of recombinant human follicle stimulating 
hormone (Org 32489), Metrodin and Metrodin-HP. Hum Reprod. 
1995;10(7):1928–1935.
27.  Mitchell R, Bauerfeld C, Schaefer F, Scharer K, Robertson WR. Less 
acidic forms of luteinizing hormone are associated with lower testos-
terone secretion in men on haemodialysis treatment. Clin Endocrinol 
(Oxf). 1994;41(1):65–73.
28.  Chappel SC. Heterogeneity of follicle stimulating hormone: control 
and physiological function. Hum Reprod Update. 1995;5:479–487.
29.  Zambrano E, Olivares A, Mendez JP, et al. Dynamics of basal and 
gonadotropin-releasing hormone-releasable serum follicle-stimulating 
hormone charge isoform distribution throughout the human menstrual 
cycle. J Clin Endocrinol Metab. 1995;80(5):1647–1656.
30.  Anobile CJ, Talbot JA, McCann SJ, Padmanabhan V , Robertson WR. 
Glycoform composition of serum gonadotrophins through the normal 
menstrual cycle and in the post-menopausal state. Mol Hum Reprod. 
1998;4(7):631–639.
31.  Bishop LA, Nguyen TV, Schofield PR. Both of the beta-subunit 
carbohydrate residues of follicle-stimulating hormone determine 
the metabolic clearance rate and in vivo potency. Endocrinology. 
1995;136(6):2635–2640.
32.  Dhillon S, Keating GM. Lutropin alfa. Drugs. 2008;68(11):1529–1540.
33.  Loumaye E, Engrand P, Howles CM, O’Dea L. Assessment of the 
role of serum luteinizing hormone and estradiol response to follicle-
stimulating hormone on in vitro fertilization treatment outcome. Fertil 
Steril. 1997;67(5):889–899.
34.  Weston AM, Zelinski-Wooten MB, Hutchison JS, Stouffer RL, 
Wolf DP. Developmental potential of embryos produced by in-vitro 
fertilization from gonadotrophin-releasing hormone antagonist-treated 
macaques stimulated with recombinant human follicle stimulating 
hormone alone or in combination with luteinizing hormone. Hum 
Reprod. 1996;11(3):608–613.
35.  Zelinski-Wooten MB, Hutchison JS, Hess DL, Wolf DP, Stouffer RL. 
Follicle stimulating hormone alone supports follicle growth and oocyte 
development in gonadotrophin-releasing hormone antagonist-treated 
monkeys. Hum Reprod. 1995;10(7):1658–1666.
36.  Burgues S. Spanish Collaborative Group on Female Hypogonadotrophic 
Hypogonadism. The effectiveness and safety of recombinant human 
LH to support follicular development induced by recombinant human 
FSH in WHO group I anovulation: evidence from a multicentre study 
in Spain. Hum Reprod. 2001;16(12):2525–2532.
37.  Recombinant LH Study Group. Does the addition of recombinant LH in 
WHO group II anovulatory women over-responding to FSH treatment 
reduce the number of developing follicles? A dose-finding study. Hum 
Reprod. 2005;20(3):629–635.
38.  Loumaye E. Ovarian stimulation: is exogenous LH necessary in all 
patients? Gynecol Obstet Fertil. 2002;30(11):890–895.
39.  Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical 
evidence for an LH ceiling? Hum Reprod. 2003;18(12):2719–2720.
40.  Lockwood GM, Muttukrishna S, Groome NP, Knight PG, Ledger WL.   
Circulating inhibins and activin A during GnRH-analogue down-
regulation and ovarian hyperstimulation with recombinant FSH 
for in-vitro fertilization-embryo transfer. Clin Endocrinol (Oxf). 
1996;45(6):741–748.
41.  Fisch B, Avrech OM, Pinkas H, et al. Superovulation before IVF 
by recombinant versus urinary human FSH (combined with a long 
GnRH analog protocol): a comparative study. J Assist Reprod Genet. 
1995;12(1):26–31.
42.  le Cotonnec JY, Loumaye E, Porchet HC, Beltrami V , Munafo A. Phar-
macokinetic and pharmacodynamic interactions between recombinant 
human luteinizing hormone and recombinant human follicle-stimulating 
hormone. Fertil Steril. 1998;69(2):201–209.
43.  Karlsson MO, Wade JR, Loumaye E, Munafo A. The population 
pharmacokinetics of recombinant- and urinary-human follicle stimulat-
ing hormone in women. Br J Clin Pharmacol. 1998;45(1):13–20.
44.  le Cotonnec JY, Porchet HC, Beltrami V , Munafo A. Clinical pharma-
cology of recombinant human luteinizing hormone: Part I. Pharmaco-
kinetics after intravenous administration to healthy female volunteers 
and comparison with urinary human luteinizing hormone. Fertil Steril. 
1998;69(2):189–194.Biologics: Targets & Therapy 2010:4 14
Gibreel and Bhattacharya Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
45.  le Cotonnec JY, Porchet HC, Beltrami V , Khan A, Toon S, Rowland M. 
Clinical pharmacology of recombinant human follicle-stimulating 
hormone (FSH). I. Comparative pharmacokinetics with urinary human 
FSH. Fertil Steril. 1994;61(4):669–678.
46.  Baer G, Loumaye E. Comparison of recombinant human luteinising 
hormone (r-hLH) and human menopausal gonadotropin (hMG) in assisted 
reproductive technology. Curr Med Res Opin. 2003;19(2):83–88.
47.  Siebold B. Physicochemical characterization of recombinant human 
follicle stimulating hormone. Hum Reprod. 1996;11 Suppl:1109–1115; 
discussion 117–119.
48.  Driebergen R, Baer G. Quantification of follicle stimulating hormone 
(follitropin alfa): is in vivo bioassay still relevant in the recombinant 
age? Curr Med Res Opin. 2003;19(1):41–46.
49.  Lispi M, Bassett R, Crisci C, et al. Comparative assessment of the 
consistency and quality of a highly purified FSH extracted from human 
urine (urofollitropin) and a recombinant human FSH (follitropin 
alpha). Reprod Biomed Online. 2006;13(2):179–193.
50.  Lass A, McVeigh E; UK Gonal-f FbM PMS Group. Routine use of 
r-hFSH follitropin alfa filled-by-mass for follicular development for 
IVF: a large multicentre observational study in the UK. Reprod Biomed 
Online. 2004;9(6):604–610.
51.  Wikland M, Hugues JN, Howles C. Improving the consistency of 
ovarian stimulation: follitropin alfa filled-by-mass. Reprod Biomed 
Online. 2006;12(6):663–668.
52.  Keck C, Bassett R, Ludwig M. Factors influencing response to ovarian 
stimulation. Reprod Biomed Online. 2005;11(5):562–569.
53.  http//www.fda.gov/cder/foi/label/2004/21322/lbl.pdf
54.  Dickey RP. Strategies to reduce multiple pregnancies due to ovulation 
stimulation. Fertil Steril. 2009;91(1):1–17.
55.  Van Loon K. Safety of high doses of recombinant human growth 
hormone. Horm Res. 1998;49(# Suppl 2):78–81.
56.  Hugues JN. Recombinant human follicle-stimulating hormone: a scientific 
step to clinical improvement. Reprod Biomed Online. 2001;2(1):54–64.
57.  Recombinant Human FSH Study Group. Clinical assessment of 
recombinant human follicle-stimulating hormone in stimulating 
ovarian follicular development before in vitro fertilization. Fertil Steril. 
1995;63(1):77–86.
58.  Bergh C, Howles CM, Borg K, et al. Recombinant human follicle 
stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary 
FSH (Metrodin HP): results of a randomized comparative study in 
women undergoing assisted reproductive techniques. Hum Reprod. 
1997;12(10):2133–2139.
59.  Balen A, Platteau P, Andersen AN, Devroey P, Helmgaard L, 
Arce JC; for the Bravelle Ovulation Induction (BOI) Study Group. 
Highly purified FSH is as efficacious as recombinant FSH for ovula-
tion induction in women with WHO Group II anovulatory infertility: 
a randomized controlled non-inferiority trial. Hum Reprod. 2007;22(7): 
1816–1823.
60.  Loret de Mola JR, Kiwi R, Austin C, Goldfarb JM. Subclavian deep vein 
thrombosis associated with the use of recombinant follicle-stimulating 
hormone (Gonal-F) complicating mild ovarian hyperstimulation 
syndrome. Fertil Steril. 2000;73(6):1253–1256.
61.  Bar J, Orvieto R, Lahav J, Hod M, Kaplan B, Fisch B. Effect of urinary 
versus recombinant follicle-stimulating hormone on platelet function 
and other hemostatic variables in controlled ovarian hyperstimulation. 
Fertil Steril. 2004;82(6):1564–1569.
62.  Hedon B, Hugues JN, Emperaire JC, et al. A comparative prospective 
study of a chronic low dose versus a conventional ovulation stimula-
tion regimen using recombinant human follicle stimulating hormone in 
anovulatory infertile women. Hum Reprod. 1998;13(10):2688–2692.
63.  Harrison S, Wolf T, Abuzeid MI. Administration of recombinant follicle 
stimulating hormone in a woman with allergic reaction to menotropin: 
a case report. Gynecol Endocrinol. 2000;14(3):149–152.
64.  Phipps WR, Holden D, Sheehan RK. Use of recombinant human 
follicle-stimulating hormone for in vitro fertilization-embryo transfer 
after severe systemic immunoglobulin E-mediated reaction to urofol-
litropin. Fertil Steril. 1996;66(1):148–150.
65.  Brinsden P, Akagbosu F, Gibbons LM, et al. A comparison of the 
efficacy and tolerability of two recombinant human follicle-stimulating 
hormone preparations in patients undergoing in vitro fertilization-
embryo transfer. Fertil Steril. 2000;73(1):114–116.
66.  Orvieto R, Nahum R, Rabinson J, Ashkenazi J, Anteby EY, Meltcer S. 
Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled 
ovarian hyperstimulation for in vitro fertilization: is there any differ-
ence? Fertil Steril. 2009;91(4 Suppl):1522–1525.
67.  Fried G, Harlin J, Wramsby H. Recombinant FSH – clinical experience 
with two different preparations. Fertil Steril. 1998;70 Suppl 1:S112.
68.  Egbase PE. Severe OHSS: how many cases are preventable? Hum 
Reprod. 2000;15(1):8–10.
69.  Aboulghar M, Evers JH, Al-Inany H. Intravenous albumin for prevent-
ing severe ovarian hyperstimulation syndrome: a Cochrane review. Hum 
Reprod. 2002;17(12):3027–3032.
70.  Buyalos RP, Lee CT. Polycystic ovary syndrome: pathophysiology and 
outcome with in vitro fertilization. Fertil Steril. 1996;65(1):1–10.
71.  MacDougall MJ, Tan SL, Balen A, Jacobs HS. A controlled study 
comparing patients with and without polycystic ovaries undergoing 
in-vitro fertilization. Hum Reprod. 1993;8(2):233–237.
72.  Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe ovarian 
hyperstimulation syndrome using agonists of gonadotropin-releasing 
hormone for in vitro fertilization: a European series and a proposal for 
prevention. Fertil Steril. 1990;53(3):502–509.
73.  Fauser BC,Van Heusden AM. Manipulation of human ovarian function: 
physiological concepts and clinical consequences. Endocr Rev. 
1997;18(1):71–106.
74.  Balasch J, Fabregues F, Penarrubia J, et al. Outcome from consecu-
tive assisted reproduction cycles in patients treated with recombinant 
follitropin alfa filled-by-bioassay and those treated with recombinant 
follitropin alfa filled-by-mass. Reprod Biomed Online. 2004;8(4): 
408–413.
75.  Balasch J, Penarrubia J, Fabregues F, et al. Ovarian responses to recom-
binant FSH or HMG in normogonadotrophic women following pituitary 
desensitization by a depot GnRH agonist for assisted reproduction. 
Reprod Biomed Online. 2003;7(1):35–42.
76.  European and Israeli Study Group on Highly Purified Menotropin 
versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety 
of highly purified menotropin versus recombinant follicle-stimulating 
hormone in in vitro fertilization/intracytoplasmic sperm injection 
cycles: a randomized, comparative trial. Fertil Steril. 2002;78(3): 
520–528.
77.  Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. 
Efficacy and safety of human menopausal gonadotrophins versus recom-
binant FSH: a meta-analysis. Reprod Biomed Online. 2008;16(1):81–88.
78.  Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, 
van Wely M. Urinary hMG versus recombinant FSH for controlled 
ovarian hyperstimulation following an agonist long down-regulation 
protocol in IVF or ICSI treatment: a systematic review and meta-
analysis. Hum Reprod. 2008;23(2):310–315.
79.  Mochtar MH, Van der V, Ziech M, van Wely M. Recombinant 
Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation 
in assisted reproductive cycles. Cochrane Database Syst Rev. 2007;2:
CD005070.
80.  Timeva T, Milachich T, Antonova I, Arabaji T, Shterev A, Omar HA. 
Correlation between number of retrieved oocytes and pregnancy rate 
after in vitro fertilization/intracytoplasmic sperm infection. Scientific 
WorldJournal. 2006;6686–690.
81.  van Rumste MM, Custers IM, van der Veen F, van Wely M, Evers JL, 
Mol BW. The influence of the number of follicles on pregnancy rates 
in intrauterine insemination with ovarian stimulation: a meta-analysis. 
Hum Reprod Update. 2008;14(6):563–570.
82.  Sedbon E, Wainer R, Perves C. Quality of life of patients undergoing 
ovarian stimulation with injectable drugs in relation to medical practice 
in France. Reprod Biomed Online. 2006;12(3):298–303.
83.  Palermo R. Differential actions of FSH and LH during folliculogenesis. 
Reprod Biomed Online. 2007;15(3):326–337.Biologics: Targets & Therapy 2010:4 1
recombinant follitropin alfa/lutropin alfa in fertility treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  84.  O’Dea L, O’Brien F, Currie K, Hemsey G. Follicular development 
induced by recombinant luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) in anovulatory women with LH and 
FSH deficiency: evidence of a threshold effect. Curr Med Res Opin. 
2008;24(10):2785–2793.
  85.  Kliesch S, Behre HM, Nieschlag E. Recombinant human follicle-
stimulating hormone and human chorionic gonadotropin for induc-
tion of spermatogenesis in a hypogonadotropic male. Fertil Steril. 
1995;63(6):1326–1328.
  86.  Arslan AA, Gu Y, Zeleniuch-Jacquotte A, et al. Reproducibility of 
serum pituitary hormones in women. Cancer Epidemiol Biomarkers 
Prev. 2008;17(8):1880–1883.
  87.  Dhont M, Onghena A, Coetsier T, De Sutter P. Prospective random-
ized study of clomiphene citrate and gonadotrophins versus goserelin 
and gonadotrophins for follicular stimulation in assisted reproduction. 
Hum Reprod. 1995;10(4):791–796.
  88.  Steures P, van der Steeg JW, Hompes PG, et al. Intra-uterine insemi-
nation with controlled ovarian hyperstimulation compared to an 
expectant management in couples with unexplained subfertility and an 
intermediate prognosis: a randomised study. Ned Tijdschr Geneeskd. 
2008;152(27):1525–1531.
  89.  Bensdorp AJ, Cohlen BJ, Heineman MJ, Vandekerckhove P. Intra-
uterine insemination for male subfertility. Cochrane Database Syst 
Rev. 2007;4(4):CD000360.
  90.  Barlow DH. GnRH agonists and in vitro fertilization. J Reprod Med. 
1998;43(3 Suppl):245–251.
  91.  Sbracia M, Colabianchi J, Giallonardo A, et al. Cetrorelix protocol 
versus gonadotropin-releasing hormone analog suppression long pro-
tocol for superovulation in intracytoplasmic sperm injection patients 
older than 40. Fertil Steril. 2009;91(5):1842–1847.
  92.  Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. 
Eur J Obstet Gynecol Reprod Biol. 2004;115 Suppl 1:S44–S56.
  93.  Kingsland C, Tan SL, Bickerton N, Mason B, Campbell S. The rou-
tine use of gonadotropin-releasing hormone agonists for all patients 
undergoing in vitro fertilization. Is there any medical advantage? 
A prospective randomized study. Fertil Steril. 1992;57(4):804–809.
  94.  Broekmans FJ, Bernardus RE, Berkhout G, Schoemaker J. Pituitary 
and ovarian suppression after early follicular and mid-luteal admin-
istration of a LHRH agonist in a depot formulation: decapeptyl CR. 
Gynecol Endocrinol. 1992;6(3):153–161.
  95.  Abdalla HI, Ahuja KK, Leonard T, Morris NN, Honour JW, Jacobs HS. 
Comparative trial of luteinizing hormone-releasing hormone analog/
human menopausal gonadotropin and clomiphene citrate/human 
menopausal gonadotropin in an assisted conception program. Fertil 
Steril. 1990;53(3):473–478.
  96.  De Placido G, Alviggi C, Mollo A, Strina I, Varricchio MT, 
Molis M. Recombinant follicle stimulating hormone is effective in 
poor responders to highly purified follicle stimulating hormone. Hum 
Reprod. 2000;15(1):17–20.
  97.  Mohamed MA, Sbracia M, Pacchiarotti A, et al. Urinary follicle-stimulating 
hormone (FSH) is more effective than recombinant FSH in older women 
in a controlled randomized study. Fertil Steril. 2006;85(5):1398–1403.
  98.  Hompes PG, Broekmans FJ, Hoozemans DA, Schats R, FIRM group. 
Effectiveness of highly purified human menopausal gonadotropin 
vs recombinant follicle-stimulating hormone in first-cycle in vitro 
fertilization-intracytoplasmic sperm injection patients. Fertil Steril. 
2008;89(6):1685–1693.
  99.  Bosch E, Vidal C, Labarta E, Simon C, Remohi J, Pellicer A. Highly 
purified hMG versus recombinant FSH in ovarian hyperstimula-
tion with GnRH antagonists – a randomized study. Hum Reprod. 
2008;23(10):2346–2351.
100.  Shoham Z, Insler V. Recombinant technique and gonadotropins 
production: new era in reproductive medicine. Fertil Steril. 
1996;66(2):187–201.
101.  Tulppala M, Aho M, Tuuri T, et al. Comparison of two recombinant 
follicle-stimulating hormone preparations in in-vitro fertilization: 
a randomized clinical study. Hum Reprod. 1999;14(11):2709–2715.
102.  Harlin J, Csemiczky G, Wramsby H, Fried G. Recombinant follicle 
stimulating hormone in in-vitro fertilization treatment-clinical 
experience with follitropin alpha and follitropin beta. Hum Reprod. 
2000;15(2):239–244.
103.  Platteau P, Andersen AN, Balen A, et al; Menopur Ovulation 
Induction (MOI) Study Group. Similar ovulation rates, but dif-
ferent follicular development with highly purified menotrophin 
compared with recombinant FSH in WHO Group II anovulatory 
infertility: a randomized controlled study. Hum Reprod. 2006;21(7): 
1798–1804.
104.  Kolibianakis E, Zikopoulos K, Albano C, et al. Reproductive outcome 
of polycystic ovarian syndrome patients treated with GnRH antago-
nists and recombinant FSH for IVF/ICSI. Reprod Biomed Online. 
2003;7(3):313–318.
105.  Watson H, Kiddy DS, Hamilton-Fairley D, et al. Hypersecretion of 
luteinizing hormone and ovarian steroids in women with recurrent 
early miscarriage. Hum Reprod. 1993;8(6):829–833.
106.  Oliveira JB, Mauri AL, Petersen CG, et al. Recombinant lutein-
izing hormone supplementation to recombinant follicle-stimulation 
hormone during induced ovarian stimulation in the GnRH-agonist 
protocol: a meta-analysis. J Assist Reprod Genet. 2007;24(2–3): 
67–75.
107.  Barrenetxea G, Agirregoikoa JA, Jimenez MR, de Larruzea AL, 
Ganzabal T, Carbonero K. Ovarian response and pregnancy outcome 
in poor-responder women: a randomized controlled trial on the effect 
of luteinizing hormone supplementation on in vitro fertilization cycles. 
Fertil Steril. 2008;89(3):546–553.
108.  Kolibianakis EM, Kalogeropoulou L, Griesinger G, et al. Among 
patients treated with FSH and GnRH analogues for in vitro fertilization, 
is the addition of recombinant LH associated with the probability 
of live birth? A systematic review and meta-analysis. Hum Reprod 
Update. 2007;13(5):445–452.
109.  Durnerin CI, Erb K, Fleming R, et al; Luveris Pretreatment Group. Effects 
of recombinant LH treatment on folliculogenesis and responsiveness to 
FSH stimulation. Hum Reprod. 2008;23(2):421–426.
110.  Picard M, Rossier C, Papasouliotis O, Lugan I. Bioequivalence of 
recombinant human FSH and recombinant human LH in a fixed 2:1 
combination: two phase I, randomised, crossover studies. Curr Med 
Res Opin. 2008;24(4):1199–1208.
111.  Lachelin GC, Yen SS. Hypothalamic chronic anovulation. Am J Obstet 
Gynecol. 1978;130(7):825–831.
112.  Homburg R. Ovulation induction. Expert Opin Pharmacother. 
2003;4(11):1995–2004.
113.  Filicori M, Flamigni C, Cognigni G, Dellai P, Michelacci L, Arnone R. 
Increased insulin secretion in patients with multifollicular and poly-
cystic ovaries and its impact on ovulation induction. Fertil Steril. 
1994;62(2):279–285.
114.  The ESHRE Capri Workshop Group. Anovulatory infertility. Hum 
Reprod. 1995;10(6):1549–1553.
115.  Shoham Z, Smith H, Yeko T, O’Brien F, Hemsey G, O’Dea L. Recom-
binant LH (lutropin alfa) for the treatment of hypogonadotrophic 
women with profound LH deficiency: a randomized, double-blind, 
placebo-controlled, proof-of-efficacy study. Clin Endocrinol (Oxf). 
2008;69(3):471–478.
116.  Kaufmann R, Dunn R, Vaughn T, et al. Recombinant human luteinizing 
hormone, lutropin alfa, for the induction of follicular development 
and pregnancy in profoundly gonadotrophin-deficient women. Clin 
Endocrinol (Oxf). 2007;67(4):563–569.
117.  Kousta E, White DM, Piazzi A, Loumaye E, Franks S. Successful induc-
tion ovulation and completed pregnancy using recombinant human 
luteinizing hormone and follicle stimulating hormone in a woman with 
Kallmann’s syndrome. Hum Reprod. 1996;11(1):70–71.
118.  Campo S, Campo V , Lanzone A. Twin pregnancy using recombinant 
gonadotropins in a woman with hypogonadotropic hypogonadism. 
Gynecol Endocrinol. 2002;16(1):27–32.
119.  Broekmans FJ,Fauser BC. Diagnostic criteria for polycystic ovarian 
syndrome. Endocrine. 2006;30(1):3–11.Biologics: Targets & Therapy 2010:4 1
Gibreel and Bhattacharya Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
120.  Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop 
Group. Revised 2003 consensus on diagnostic criteria and long-
term health risks related to polycystic ovary syndrome. Fertil Steril. 
2004;81(1):19–25.
121.  Hendriks ML, Brouwer J, Hompes PG, Homburg R, Lambalk CB. 
LH as a diagnostic criterion for polycystic ovary syndrome in patients 
with WHO II oligo/amenorrhoea. Reprod Biomed Online. 2008; 
16(6):765–771.
122.  Donderwinkel PF, Schoot DC, Coelingh Bennink HJ, Fauser BC. 
Pregnancy after induction of ovulation with recombinant human FSH 
in polycystic ovary syndrome. Lancet. 1992;340(8825):983.
123.  Platteau P, Andersen AN, Balen A, et al. Ovulation Induction (MOI) 
Study Group. Similar ovulation rates, but different follicular develop-
ment with highly purified menotrophin compared with recombinant 
FSH in WHO Group II anovulatory infertility: a randomized controlled 
study. Hum Reprod. 2006;21(7):1798–1804.
124.  Revelli A, Poso F, Gennarelli G, Moffa F, Grassi G, Massobrio M. Recom-
binant versus highly-purified, urinary follicle-stimulating hormone (r-FSH 
vs HP-uFSH) in ovulation induction: a prospective, randomized study 
with cost-minimization analysis. Reprod Biol Endocrinol. 2006;4:38.
125.  Yarali H, Bukulmez O, Gurgan T. Urinary follicle-stimulating hormone 
(FSH) versus recombinant FSH in clomiphene citrate-resistant, 
normogonadotropic,chronic anovulation: a prospective randomized 
study. Fertil Steril. 1999;72(2):276–281.
126.  Yarali H, Zeyneloglu HB. Gonadotrophin treatment in patients with poly-
cystic ovary syndrome. Reprod Biomed Online. 2004;8(5):528–537.
127.  Fulghesu AM, Apa R, Belosi C, et al. Recombinant versus urinary 
follicle-stimulating hormone in the low-dose regimen in anovulatory 
patients with polycystic ovary syndrome: a safer and more effective 
treatment. Horm Res. 2001;55(5):224–228.
128.  Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus 
urinary gonadotrophins or recombinant FSH for ovulation induction 
in subfertility associated with polycystic ovary syndrome. Cochrane 
Database Syst Rev. 2001;2(2):CD002121.
129.  Lopez E, Gunby J, Daya S, Parrilla JJ, Abad L, Balasch J. Ovulation 
induction in women with polycystic ovary syndrome: randomized trial 
of clomiphene citrate versus low-dose recombinant FSH as first line 
therapy. Reprod Biomed Online. 2004;9(4):382–390.
130.  Szilagyi A, Bartfai G, Manfai A, Koloszar S, Pal A, Szabo I. Low-dose 
ovulation induction with urinary gonadotropins or recombinant follicle 
stimulating hormone in patients with polycystic ovary syndrome. 
Gynecol Endocrinol. 2004;18(1):17–22. 
131.  Cristello F, Cela V , Artini PG, Genazzani AR. Therapeutic strategies 
for ovulation induction in infertile women with polycystic ovary 
syndrome. Gynecol Endocrinol. 2005;21(6):340–352.
132.  Leader A; Monofollicular Ovulation Induction Study Group. 
Improved monofollicular ovulation in anovulatory or oligo-ovulatory 
women after a low-dose step-up protocol with weekly increments of 
25 international units of follicle-stimulating hormone. Fertil Steril. 
2006;85(6):1766–1773.
133.  Attia AM, Al-Inany HG. Gonadotrophins for idiopathic male factor 
subfertility. Cochrane Database Syst Rev. 2007;(4)(4):CD005071.
134.  McLachlan RI. The endocrine control of spermatogenesis. Baillieres 
Best Pract Res Clin Endocrinol Metab. 2000;14(3):345–362.
135.  Miyagawa Y, Tsujimura A, Matsumiya K, Takao T, Tohda A, Koga M, 
et al. Outcome of gonadotropin therapy for male hypogonadotropic 
hypogonadism at university affiliated male infertility centers: a 30-year 
retrospective study. J Urol. 2005;173:2072–2075.
136.  Kamischke A, Behre HM, Bergmann M, Simoni M, Schafer T, 
Nieschlag E. Recombinant human follicle stimulating hormone for 
treatment of male idiopathic infertility: a randomized, double-blind, 
placebo-controlled, clinical trial. Hum Reprod. 1998;13(3):596–603.
137.  Foresta C, Selice R, Ferlin A, Garolla A. Recombinant FSH in the treatment 
of oligozoospermia. Expert Opin Biol Ther. 2009;9(5):659–666.
138.  Bakircioglu ME, Erden HF, Ciray HN, Bayazit N, Bahceci M. 
Gonadotrophin therapy in combination with ICSI in men with hypogonad-
otrophic hypogonadism. Reprod Biomed Online. 2007;15(2):156–160.
139.  Lee KH, Diekman MA, Moss GE, Allrich RD. Pituitary gonadotropins, 
hypothalamic gonadotropin-releasing hormone, and testicular traits 
of boars exposed to natural or supplemental lighting during pubertal 
development. Biol Reprod. 1987;36(5):1164–1169.
140.  Cailleux-Bounacer A, Reznik Y, Cauliez B, Menard JF, Duparc C, 
Kuhn JM. Evaluation of endocrine testing of Leydig cell function 
using extractive and recombinant human chorionic gonadotropin 
and different doses of recombinant human LH in normal men. Eur J 
Endocrinol. 2008;159(2):171–178.
141.  Bouloux P, Warne DW, Loumaye E. Efficacy and safety of recom-
binant human follicle-stimulating hormone in men with isolated 
hypogonadotrophic hypogonadism. Fertil Steril. 2002;77:270–273.
142.  Liu PY, Turner L, Rushford D, McDonald J, Baker HW, Conway AJ, 
et al. Efficacy and safety of recombinant human follicle stimulating 
hormone (Gonal-F) with urinary human chorionic gonadotrophin for 
induction of spermatogenesis and fertility in gonadotrophin-deficient 
men. Hum Reprod. 1999;14:1540–1545.
143.  Matsumoto AM, Snyder P, Bhasin S, Martin K,Weber T,Winters S, 
et al. Stimulation of spermatogenesis with recombinant human follicle-
stimulating hormone (follitropin alfa; GONAL-f) long-term treatment 
in azoospermic men with hypogonadotropic hypogonadism (HH). 
Fertil Steril. 2008. [Epub ahead of print]
144.  Okada H, on behalf of the Japanese MHH study group. Recombinant 
human follicle-stimulating hormone (r-hFSH, follitropin alfa) is 
efficacious for induction of spermatogenesis and pregnancy in Japanese 
men with hypogonadotropic hypogonadism. Fertil Steril. 2005; 
84(Suppl 1):S222.
145.  Warne D, Okada H, Yano Y, Koide N, Howles C. A combined analysis 
of data to identify predictive factors for spermatogenesis in men with 
hypogonadotropic hypogonadism treated with recombinant human 
follicle-stimulating hormone and human chorionic gonadotropin. 
Fertil Steril. In press 2009.
146.  Liu PY, Gebski VJ, Turner L, Conway AJ, Wishart SM, Handelsman DJ. 
Predicting pregnancy and spermatogenesis by survival analysis during 
gonadotrophin treatment of gonadotrophin-deficient infertile men. Hum 
Reprod. 2002;17:625–633.
147.  Pang S, Kaplan B, Karande V , et al; Follistim Pen Trade Mark COH 
Study Group. Administration of recombinant human FSH (solution in 
cartridge) with a pen device in women undergoing ovarian stimulation. 
Reprod Biomed Online. 2003;7(3):319–326.
148.  Pang SC. A pen injection device for self-administration of recombinant 
follicle-stimulating hormone for fertility treatments. Expert Rev Med 
Devices. 2005;2(1):27–32.
149.  Aghssa MM, Azargoon A, Ramezanzadeh F, Bagheri M. A compari-
son of the efficacy, tolerability, and convenience of two formulations 
of follitropin-alpha in Iranian woman undergoing intracytoplasmic 
sperm injection cycles. Fertil Steril. 2008;90(4):1043–1048.
150.  Porter R, Kissel C, Saunders H, Keck C. Patient and nurse evaluation 
of recombinant human follicle-stimulating hormone administration 
methods: comparison of two follitropin injection pens. Curr Med Res 
Opin. 2008;24(3):727–735.
151.  Daya S, Ledger W, Auray JP, et al. Cost-effectiveness modelling of 
recombinant FSH versus urinary FSH in assisted reproduction tech-
niques in the UK. Hum Reprod. 2001;16(12):2563–2569.
152.  Hatoum HT, Keye WR Jr, Marrs RP, Walton SM, Marshall DC. 
A Markov model of the cost-effectiveness of human-derived follicle-
stimulating hormone (FSH) versus recombinant FSH using compara-
tive clinical trial data. Fertil Steril. 2005;83(3):804–807.
153.  Sykes D, Out HJ, Palmer SJ, van Loon J. The cost-effectiveness of 
IVF in the UK: a comparison of three gonadotrophin treatments. Hum 
Reprod. 2001;16(12):2557–2562.
154.  Foresta C, Selice R, Ferlin A, Garolla A. Recombinant FSH in the treatment 
of oligozoospermia. Expert Opin Biol Ther. 2009;9(5):659–666.
155.  Lloyd A, Kennedy R, Hutchinson J, Sawyer W. Economic evalu-
ation of highly purified menotropin compared with recombinant 
follicle-stimulating hormone in assisted reproduction. Fertil Steril. 
2003;80(5):1108–1113.Biologics: Targets & Therapy 2010:4
Biologics: Targets & Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/biologics-targets--therapy-journal
Biologics: Targets & Therapy is an international, peer-reviewed 
journal focusing on the patho-physiological rationale for and clinical 
application of Biologic agents in the management of autoimmune 
diseases, cancers or other pathologies where a molecular target can 
be identified. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
1
recombinant follitropin alfa/lutropin alfa in fertility treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
156.  Wechowski J, Connolly M, McEwan P, Kennedy R. An economic 
evaluation of highly purified HMG and recombinant FSH based on a 
large randomized trial. Reprod Biomed Online. 2007;15(5):500–506.
157.  Al-Inany H, Aboulghar MA, Mansour RT, Proctor M. Recombinant 
versus urinary gonadotrophins for triggering ovulation in assisted 
conception. Hum Reprod. 2005;20(8):2061–2073.
158.  Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, 
Serour GI. HMG versus rFSH for ovulation induction in developing 
countries: a cost-effectiveness analysis based on the results of a recent 
meta-analysis. Reprod Biomed Online. 2006;12(2):163–169.
159.  Gerli S, Casini ML, Unfer V, Costabile L, Bini V, Di Renzo GC. 
Recombinant versus urinary follicle-stimulating hormone in intra-
uterine insemination cycles: a prospective, randomized analysis of 
cost effectiveness. Fertil Steril. 2004;82(3):573–578.
160.  Gerli S, Bini V, Di Renzo GC. Cost-effectiveness of recombinant 
follicle-stimulating hormone (FSH) versus human FSH in intrauterine 
insemination cycles: a statistical model-derived analysis. Gynecol 
Endocrinol. 2008;24(1):18–23.
161.  Shetty A. Disorders of ovulation. In: Templeton AA. ed. Management of 
Infertility for the MRCOG and Beyond. London: RCOG press; 2001.
162.  Westergaard LG, Erb K, Laursen SB, Rex S, Rasmussen PE. Human 
menopausal gonadotropin versus recombinant follicle-stimulating 
hormone in normogonadotropic women down-regulated with a 
gonadotropin-releasing hormone agonist who were undergoing 
in vitro fertilization and intracytoplasmic sperm injection: a prospec-
tive randomized study. Fertil Steril. 2001;76(3):543–549.
163.  Ng EH, Lau EY, Yeung WS, Ho PC. HMG is as good as recombinant 
human FSH in terms of oocyte and embryo quality: a prospective 
randomized trial. Hum Reprod. 2001;16(2):319–325.
164.  Gordon UD, Harrison RF, Fawzy M, Hennelly B, Gordon AC. 
A randomized prospective assessor-blind evaluation of luteinizing 
hormone dosage and in vitro fertilization outcome. Fertil Steril. 
2001;75(2):324–331.
165.  Kilani Z, Dakkak A, Ghunaim S, et al. A prospective, randomized, 
controlled trial comparing highly purified hMG with recombinant 
FSH in women undergoing ICSI: ovarian response and clinical 
outcomes. Hum Reprod. 2003;18(6):1194–1199.
166.  Nyboe Andersen A, Devroey P, Arce J-C, for the MERIT Group. 
Clinical outcome following stimulation with highly purified 
hMG or recombinant FSH in patients undergoing IVF: a random-
ized assessor-blind controlled trial. Hum Reprod. 2006;21(12): 
3217–3227.
167.  Coelingh Bennink HJ, Fauser BC, Out HJ. Recombinant follicle-
stimulating hormone (FSH; Puregon) is more efficient than urinary 
FSH (Metrodin) in women with clomiphene citrate-resistant, 
normogonadotropic, chronic anovulation: a prospective, multicenter, 
assessor-blind, randomized, clinical trial. European Puregon 
Collaborative Anovulation Study Group. Fertil Steril. 1998;69(1):19–
25.
168.  Loumaye E, Martineau I, Piazzi A, et al. Clinical assessment of human 
gonadotrophins produced by recombinant DNA technology. Hum 
Reprod. 1996;11 Suppl 195–107; discussion 117–119.